ArticleJournal of clinical immunology2011
Active immunological profile is associated with systemic Sjögren's syndrome.
Article in Journal of clinical immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Diagnostic performance of serology against histologic assessment to diagnose Sjogren's syndrome: a systematic review.Clinical rheumatology · 2021Pooled it
- Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.Rheumatology international · 2015Pooled it
- Predicting major organ complications in primary Sjögren's disease using a machine learning ensemble strategy: a dual-center retrospective clinical study.Frontiers in immunology · 2026Article
- Prognostic benefit of immunosuppressive agents in primary Sjögren's syndrome patients with hypergammaglobulinemia.Frontiers in immunology · 2026Article
- A retrospective study of electrocardiographic alterations in primary Sjögren's syndrome: role of anti-SSA positivity and disease duration.Clinical rheumatology · 2025Observational
- Anti-SSA/SSB antibody double-negative Sjögren's disease patients: a comprehensive clinical study and immune profile.Clinical rheumatology · 2025Observational
- Clinical Characteristics of Distinct Subgroups of Patients with Primary Sjögren's Syndrome Classified by Serological Profiles: A Comparison Study.Journal of personalized medicine · 2024Article
- Therapeutic potential for P2YPurinergic signalling · 2023Review
- Discordant Predictions of Extraglandular Involvement in Primary Sjögren's Syndrome According to the Anti-SSA/Ro60 Antibodies Detection Assay in a Cohort Study.Journal of clinical medicine · 2022Article
- Autoantibodies in Sjögren's syndrome and its classification criteria.Journal of translational autoimmunity · 2022Article
- Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjögren's syndrome: A critical review.Frontiers in immunology · 2022Review
- Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren's syndrome: An exploratory cross-sectional study.Saudi medical journal · 2021Article
- Cytokine profiles and clinical characteristics in primary Sjögren´s syndrome patient groups.Journal of clinical laboratory analysis · 2021Article
- Clinical and serological characteristics of seronegative primary Sjögren's syndrome: a comparative study.Clinical rheumatology · 2021Article
- Persistent serological activity in primary Sjögren's syndrome.Clinical rheumatology · 2020Article
- Clinical and diagnostic significance of serum immunoglobulin A rheumatoid factor in primary Sjogren's syndrome.Clinical oral investigations · 2019Article
- Role of Salivary Immune Parameters in Patients With Primary Sjögren's Syndrome.Annals of laboratory medicine · 2019Article
- Epithelial Cell Adhesion Molecule in Primary Sjögren's Syndrome Patients: Characterization and Evaluation of a Potential Biomarker.Journal of immunology research · 2019Article
- Prognostic value of Sjögren's syndrome autoantibodies.Journal of laboratory and precision medicine · 2018Article
- Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this paper was to study the evolution of primary Sjögren's syndrome (pSS) immunological profile, its impact on pSS activity and long-term evolution in a bicentric cohort of French patients with pSS (n = 445, mean age 53.6 ± 14 years, mean follow-up 76.1 ± 51 months).
methodsThis is a retrospective cohort study.
resultsTwo hundred twelve patients were Sjögren's syndrome A (SSA) positive, and 131 were both SSA and Sjögren's syndrome B (SSB) positive. Sixty-eight patients (15%) had cryoglobulinemia. Active systemic profile (i.e., hypergammaglobulinemia, rheumatoid factor (RF), and anti-Sjögren's syndrome A (anti-SSA), anti-Sjögren's syndrome B (anti-SSB) positivity), associated with multisystemic involvement, leads to an increased utilization of corticosteroid and hydroxychloroquine. Multivariate analysis pointed out independent statistical association between hypergammaglobulinemia, anti-SSA, anti-SSB, and RF. Cryoglobulinemia is associated with multi-systemic involvement, lymphoma, and pSS-related death.
conclusionThe subset of patients with active immunological profile is characterized by systemic complications leading to immunosuppressive drug utilization and polyclonal B-cell activation profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.